Frontage Laboratories, Inc.

Articles

In the discovery and investigation of novel biomarkers, tissue immunohistochemistry (IHC) studies are critical, but how do you translate the
technology into the clinical laboratory for patient testing once a biomarker target has been identified?


Tissue IHC: Translating Technology into Patient Testing After Biomarker Target is ID

http://www.appliedclinicaltrialsonline.com/act_w/R&D

In the discovery and investigation of novel biomarkers, tissue immunohistochemistry (IHC) studies are critical. The important question has been how to translate the technology into the clinical laboratory for patient testing once a biomarker target has been identified.

Dr. Nan Zhang, VP of Global Central Lab Services at Frontage Laboratories Inc., will provide a valuable update on the application of Tissue IHC in new biomarker development, selection between different types of IHC, and validation of the methodology to be used for patient testing in clinical trials.

Application of Tissue IHC in new biomarker development

Selection between different types of IHCs


Clinical Trial Study Sponsor Operation Leaders


VP, Global Central Lab Services
Frontage Laboratories, Inc

Vice President, Global Central Laboratory Services, Frontage Laboratories, Inc, 2020- Present

Provide leadership and strategic direction to global central laboratory servicesEnsure testing quality and alignment in all global central laboratory sitesEnsure laboratory safety and patient safety across global sitesEnsure laboratory compliance with all applicable regulatory agenciesImplement local organizational structures required to meet the needs of the business, drive best practice across sites, and align the interest of all partiesDrive global operational excellence and continuous improvementEnsure that all sites are equipped to align appropriately with, and deliver to, significant growth objectives

Medical Director, ACM Global laboratories, 2018 – 2020

Provide clinical oversight and direction of ACM Global Laboratory, Rochester, NYEnsure laboratory quality and compliance with all applicable regulatory agencies, including but not limited to: Collage of American pathologists (CAP), SAMSHA, CLIA, and NYSDOH.Ensure that proficiency testing, alternative assessment, and QC procedures are sufficient for the extent of testing taking place within the laboratory.Ensure patient and laboratory safetySupport clinical trial RFP review; support BD and client communicationProvide clinical trial diagnostic serviceProvide consultation service to study sponsors

Director of Hematology, Flow Cytometry, Advanced Coagulation, and Blood Bank, Rochester General Hospital, 2019- 2020

President, Western New York Society of Pathologist, 2018-2019

Assistant Professor and Associate Residency Program Director, University at Buffalo, SUNY, Department of Pathology, 2014-2018

Attending Hematopathologist and Laboratory Director, Kaleida Health, 2014-2018

Hematopathology Fellowship, City of Hope Medical Center, 2013-2014

Pathology Residency, University at Buffalo, SUNY and Cedar Sinai Medical Center, 2009-2013

Postdoctoral Fellowship, City of Hope Medical Center, 2006-2009

PhD in Pathobiology, University of Southern California, 2001-2006

Beijing Medical University, Bachelor of Medicine, 1995-2000

Webcasts

March 23rd 2022 at 11 am EST | The use of tissue IHC in the development of novel biomarkers and clinical applications. 

Frontage Laboratories, Inc.

Articles

Tissue IHC: Translating Technology into Patient Testing After Biomarker Target is ID

Tissue IHC: from R&D to Clinical Lab Testing